Skip to content
Open access

Cardiovascular versus breast cancer mortality in men with breast cancer: An age-stratified SEER competing-risk study.

Jul 2026 · Biomolecules & biomedicine · 0 citations · 13 references
Medicine

TL;DR

In men with non-metastatic breast cancer, cardiovascular cumulative incidence overtakes that of breast cancer early after diagnosis in the oldest patients, which support age-aware cardiovascular attention during survivorship but do not establish that intensified cardiovascular surveillance improves outcomes.

Abstract

Male breast cancer is rare and predominantly affects older patients, who face a substantial competing burden of cardiovascular disease. We aimed to characterize age-specific cumulative incidences of breast cancer, cardiovascular, and other-cause mortality and determine when cardiovascular cumulative incidence overtakes that of breast cancer. Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified men diagnosed with non-metastatic invasive breast cancer during 2000-2022. Cause-specific cumulative incidence was estimated using the Aalen-Johansen estimator, with cardiovascular-breast cancer differences at 5 and 10 years as the primary comparison. Factors associated with cardiovascular death were evaluated using cause-specific Cox and complementary Fine-Gray models. Among 6702 men followed for a median of 67 months, 665 cardiovascular deaths occurred. Mortality patterns were strongly age-dependent. In men aged 80 years or older, cardiovascular cumulative incidence exceeded breast cancer cumulative incidence by 4.6 percentage points at 5 years and 14.6 percentage points at 10 years. In men aged 70-79 years, the differences were not significant at either time point, although an exploratory sustained crossover occurred near 13.6 years. After adjustment, age 80 years or older was strongly associated with cardiovascular death compared with age 60-69 years (hazard ratio 8.54, 95% confidence interval 6.89-10.60); regional stage and unmarried status were also associated with higher cardiovascular mortality. In men with non-metastatic breast cancer, cardiovascular cumulative incidence overtakes that of breast cancer early after diagnosis in the oldest patients. These findings support age-aware cardiovascular attention during survivorship but do not establish that intensified cardiovascular surveillance improves outcomes.

Read PDF

Similar papers

Aug 2026

Cardiovascular disease in breast cancer patients receiving chemotherapy: epidemiology and risk factors

Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.

V. Dvorovy, L. Kováčová, M. Selvek et al. · 0 citations
Open access Aug 2026

Tumor Characteristics and Event Free Survival in Older and Younger Women with Early Breast Cancer

In a sample of women with Stage I-III breast cancer who received chemotherapy with curative intent, triple negative subtype, smoking history, tumor size, and surgery type were significantly associated with shorter five-year event free survival.

Samantha Kodikara, Alexis C. Wardell, A. Deal et al. · 0 citations
Open access Aug 2026

Cardiovascular-Related Death Among Women With Breast Cancer in the United States: Do We Need a Better Approach for Estimating Rates?

These estimates were more intuitive than those from previous studies because they correctly reflected an elevated, rather than reduced, risk relative to the general population: the age-adjusted CVD-related death rate per 100 000 women with breast cancer was 1078.1 in 1999 and 733.1 in 2020.

Le Nguyen, Yan Liu, Chanhyun Park · 0 citations
Jul 2026

Risk of Primary Lung Cancer in Women with Personal History of Breast Cancer and Subsequent Treatment Modality in an Integrated Health System.

Lung cancer risk among breast cancer survivors has increased over time, however risk was driven by patient-level factors, rather than breast cancer treatment exposures, rather than lung cancer treatment exposures.

Andrea M. Gochi, Tanran Wang, Hyunjee V. Kwak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.